NO323229B1 - Flytende eller faste farmasoytiske preparater inneholdende cilansetron stabilisert mot racemisering, anvendelse av sure tilsetningsstoffer til stabiliseringen og fremgangsmate for fremstilling av slike faste preparater - Google Patents
Flytende eller faste farmasoytiske preparater inneholdende cilansetron stabilisert mot racemisering, anvendelse av sure tilsetningsstoffer til stabiliseringen og fremgangsmate for fremstilling av slike faste preparater Download PDFInfo
- Publication number
- NO323229B1 NO323229B1 NO19983540A NO983540A NO323229B1 NO 323229 B1 NO323229 B1 NO 323229B1 NO 19983540 A NO19983540 A NO 19983540A NO 983540 A NO983540 A NO 983540A NO 323229 B1 NO323229 B1 NO 323229B1
- Authority
- NO
- Norway
- Prior art keywords
- acid
- cilansetron
- solid
- preparations
- physiologically compatible
- Prior art date
Links
- NCNFDKWULDWJDS-OAHLLOKOSA-N cilansetron Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 NCNFDKWULDWJDS-OAHLLOKOSA-N 0.000 title claims description 86
- 229960002099 cilansetron Drugs 0.000 title claims description 86
- 238000002360 preparation method Methods 0.000 title claims description 60
- 239000000654 additive Substances 0.000 title claims description 55
- 230000002378 acidificating effect Effects 0.000 title claims description 54
- 239000007787 solid Substances 0.000 title claims description 53
- 239000007788 liquid Substances 0.000 title claims description 37
- 230000006340 racemization Effects 0.000 title claims description 21
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 230000006641 stabilisation Effects 0.000 title description 10
- 238000011105 stabilization Methods 0.000 title description 10
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002253 acid Substances 0.000 claims description 70
- 150000003839 salts Chemical class 0.000 claims description 49
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 230000000996 additive effect Effects 0.000 claims description 22
- 229940093915 gynecological organic acid Drugs 0.000 claims description 19
- 150000007524 organic acids Chemical class 0.000 claims description 19
- 235000005985 organic acids Nutrition 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- JXQUEAGLZNCBHC-QCUBGVIVSA-N cilansetron hydrochloride Chemical compound O.Cl.CC1=NC=CN1C[C@@H]1C(=O)C(C=2C=3N4CCCC=3C=CC=2)=C4CC1 JXQUEAGLZNCBHC-QCUBGVIVSA-N 0.000 claims description 9
- 150000007513 acids Chemical class 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000000969 carrier Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000007979 citrate buffer Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000000087 stabilizing effect Effects 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 150000007519 polyprotic acids Polymers 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229940099563 lactobionic acid Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 14
- 238000003860 storage Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- -1 acetic acid Chemical class 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 150000008043 acidic salts Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 150000008163 sugars Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19733271 | 1997-08-01 | ||
| DE19813661A DE19813661A1 (de) | 1997-08-01 | 1998-03-27 | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO983540D0 NO983540D0 (no) | 1998-07-31 |
| NO983540L NO983540L (no) | 1999-02-02 |
| NO323229B1 true NO323229B1 (no) | 2007-02-05 |
Family
ID=7837672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19983540A NO323229B1 (no) | 1997-08-01 | 1998-07-31 | Flytende eller faste farmasoytiske preparater inneholdende cilansetron stabilisert mot racemisering, anvendelse av sure tilsetningsstoffer til stabiliseringen og fremgangsmate for fremstilling av slike faste preparater |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5977127A (ja) |
| EP (1) | EP0895782B1 (ja) |
| JP (1) | JP4324260B2 (ja) |
| KR (1) | KR100515201B1 (ja) |
| CN (1) | CN1117565C (ja) |
| AR (1) | AR010178A1 (ja) |
| AT (1) | ATE283706T1 (ja) |
| AU (1) | AU743043B2 (ja) |
| BR (1) | BR9803730A (ja) |
| CA (1) | CA2244389C (ja) |
| CZ (1) | CZ295072B6 (ja) |
| DE (2) | DE19813661A1 (ja) |
| DK (1) | DK0895782T3 (ja) |
| DZ (1) | DZ2560A1 (ja) |
| ES (1) | ES2234051T3 (ja) |
| HK (1) | HK1017611A1 (ja) |
| HU (1) | HUP9801712A3 (ja) |
| ID (1) | ID20685A (ja) |
| IL (1) | IL125403A (ja) |
| NO (1) | NO323229B1 (ja) |
| NZ (1) | NZ331083A (ja) |
| PL (1) | PL191767B1 (ja) |
| PT (1) | PT895782E (ja) |
| RU (1) | RU2199318C2 (ja) |
| SK (1) | SK284916B6 (ja) |
| TR (1) | TR199801432A3 (ja) |
| TW (1) | TW509570B (ja) |
| UA (1) | UA62924C2 (ja) |
| ZA (1) | ZA986715B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452545B2 (en) * | 2001-11-13 | 2008-11-18 | Yu Ruey J | Oligosaccharide aldonic acids and their topical use |
| AU2002304784A1 (en) * | 2001-03-26 | 2002-10-08 | Novartis Pharma Gmbh | Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| GB0216027D0 (en) * | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
| EP1567163B1 (en) * | 2003-01-13 | 2007-04-11 | Dynogen Pharmaceuticals Inc. | Method of treating nausea, vomiting, retching or any combination thereof |
| EP1558081A4 (en) * | 2003-01-13 | 2006-06-14 | Dynogen Pharmaceuticals Inc | METHOD OF TREATING FUNCTIONAL INTESTINAL DISORDERS |
| JP2006522144A (ja) * | 2003-04-04 | 2006-09-28 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 下部尿路障害の治療方法 |
| US7820690B2 (en) * | 2004-03-19 | 2010-10-26 | Solvay Pharmaceuticals Gmbh | Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist |
| US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| EP2327406A4 (en) * | 2008-08-14 | 2014-04-09 | Kyorin Seiyaku Kk | STABILIZED PHARMACEUTICAL COMPOSITION |
| EP4062973A4 (en) | 2019-11-20 | 2023-11-29 | Shionogi & Co., Ltd | SOLID FORMULATION CONTAINING 6,7-UNSATURATED-7-CARBAMOYL MORPHINAND DERIVATIVE |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2059491T3 (es) * | 1987-06-29 | 1994-11-16 | Duphar Int Res | Derivados de indol con anillos condensados. |
| DE4238553A1 (de) * | 1992-11-14 | 1994-05-19 | Kali Chemie Pharma Gmbh | Neue Imidazol-1-yl-Verbindungen enthaltende Arzneimittel |
| AU702594B2 (en) * | 1995-10-13 | 1999-02-25 | Duphar International Research B.V. | Process for the preparation of enantiomerically pure imidazolyl compounds |
-
1998
- 1998-03-27 DE DE19813661A patent/DE19813661A1/de not_active Withdrawn
- 1998-06-05 CN CN98109652A patent/CN1117565C/zh not_active Expired - Fee Related
- 1998-06-17 TW TW087109651A patent/TW509570B/zh not_active IP Right Cessation
- 1998-06-18 AR ARP980102904A patent/AR010178A1/es active IP Right Grant
- 1998-07-11 KR KR10-1998-0028014A patent/KR100515201B1/ko not_active IP Right Cessation
- 1998-07-15 DZ DZ980170A patent/DZ2560A1/xx active
- 1998-07-20 IL IL12540398A patent/IL125403A/en not_active IP Right Cessation
- 1998-07-22 ES ES98113643T patent/ES2234051T3/es not_active Expired - Lifetime
- 1998-07-22 PT PT98113643T patent/PT895782E/pt unknown
- 1998-07-22 DE DE59812317T patent/DE59812317D1/de not_active Expired - Lifetime
- 1998-07-22 DK DK98113643T patent/DK0895782T3/da active
- 1998-07-22 EP EP98113643A patent/EP0895782B1/de not_active Expired - Lifetime
- 1998-07-22 AT AT98113643T patent/ATE283706T1/de active
- 1998-07-23 TR TR1998/01432A patent/TR199801432A3/tr unknown
- 1998-07-24 SK SK1009-98A patent/SK284916B6/sk not_active IP Right Cessation
- 1998-07-24 NZ NZ331083A patent/NZ331083A/xx not_active IP Right Cessation
- 1998-07-27 CZ CZ19982367A patent/CZ295072B6/cs not_active IP Right Cessation
- 1998-07-28 ZA ZA986715A patent/ZA986715B/xx unknown
- 1998-07-29 RU RU98114668/14A patent/RU2199318C2/ru not_active IP Right Cessation
- 1998-07-29 HU HU9801712A patent/HUP9801712A3/hu unknown
- 1998-07-31 UA UA98074202A patent/UA62924C2/uk unknown
- 1998-07-31 AU AU78630/98A patent/AU743043B2/en not_active Ceased
- 1998-07-31 BR BR9803730-7A patent/BR9803730A/pt not_active Application Discontinuation
- 1998-07-31 US US09/126,751 patent/US5977127A/en not_active Expired - Lifetime
- 1998-07-31 CA CA002244389A patent/CA2244389C/en not_active Expired - Fee Related
- 1998-07-31 JP JP21707598A patent/JP4324260B2/ja not_active Expired - Fee Related
- 1998-07-31 PL PL327786A patent/PL191767B1/pl not_active IP Right Cessation
- 1998-07-31 NO NO19983540A patent/NO323229B1/no not_active IP Right Cessation
- 1998-08-03 ID IDP981075A patent/ID20685A/id unknown
-
1999
- 1999-06-30 HK HK99102775A patent/HK1017611A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4743450A (en) | Stabilized compositions | |
| US4665081A (en) | Solid nifedipine preparations and a process for preparing same | |
| US5151433A (en) | Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations | |
| US4929605A (en) | Pharmaceutical composition for piperidinoalkanol derivatives | |
| KR101682963B1 (ko) | 4,5-에폭시모르피난 유도체를 함유하는 안정한 정제 | |
| JPH11514629A (ja) | 安定な甲状腺ホルモン含有薬剤 | |
| JP2002529407A (ja) | Ｌ−ｄｏｐａエチルエステル含有分散性組成物 | |
| SK8632002A3 (en) | Matrix tablet for sustained release of trimetazidine after oral administration | |
| NO323229B1 (no) | Flytende eller faste farmasoytiske preparater inneholdende cilansetron stabilisert mot racemisering, anvendelse av sure tilsetningsstoffer til stabiliseringen og fremgangsmate for fremstilling av slike faste preparater | |
| KR20070044323A (ko) | 보관안정성이 개선된 클로피도그렐 황산수소염 함유 경구용제제 | |
| US20070155780A1 (en) | Stabilized composition containing 4-amino-5-chloro-n-[(1r, 3r, 5s)-8-methyl-8-azabicyclo[3.2.1]oct-3-y1]-2-[1-methylbut-2-ynyloxy]benzamide | |
| EP2101742B1 (en) | Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form | |
| US5091191A (en) | Pharmaceutical composition with improved dissolution property | |
| KR20110092804A (ko) | 피타바스타틴 칼슘염을 함유하는 약학 조성물 | |
| WO2007134845A2 (en) | Olanzapine pharmaceutical composition | |
| EP1906931B1 (en) | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof | |
| EP4233849A1 (en) | Pharmaceutical composition comprising pomalidomide | |
| EP1560568B1 (en) | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate | |
| US6861071B2 (en) | Highly absorptive solid preparation | |
| CA2286904A1 (en) | Pharmaceutical tablet of amiodarone salt | |
| MXPA98006166A (en) | Pharmaceutical preparations of cilansetron stabilized against the racemizac | |
| US20050064029A1 (en) | Stable pharmaceutical composition | |
| CN108853033A (zh) | 一种喹硫平药物制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |